Cancer in Nursing Home Residents
Cancer is a disease of the elderly. Cancer incidence is 11-fold higher in persons over the age of 65, than in younger ones. Approximately 60% of all cancers and 70% of cancer mortality occurs in people older than 65 years. Moreover, due to the aging of the population in the Western world the number of elderly people is expected to increase and therefore the number of older cancer patients is expected to rise. Despite this rapid increase in cancer incidence and cancer-related mortality with age, our knowledge about ageing and cancer and about optimal treatment for older cancer patients is still far from adequate. Therefore, it is clear that cancer in the elderly is a major and increasing health problem. A key problem in geriatric oncology research is the important selection bias because very old/frail patients, are very rarely included in clinical trials.
Changes in the patterns of health care delivery have shifted the care of the elderly from acute care settings to the community and long-term care facilities. As the European population ages, more and more people will become nursing home residents, many of whom will have a suspicion of, or be diagnosed with, and eventually die from, cancer. Although cancer is very common in elderly nursing home residents, it is poorly studied. This lack of information may impact on clinical decision making and the appropriateness of treatments offered and therefore collection of this information is needed.
This project has two main objectives. The first objective is to report on demographics, referral patterns and motives for non-referral, anti-cancer treatments and outcome of patients in nursing homes with suspected or diagnosed active invasive cancer where a diagnostic or treatment decision has to be taken. The second objective is to develop better prognostic tools (for survival) including biological markers of ageing to help treatment decisions in the elderly.
Armonea Nursing Homes Residents
|Study Type:||Observational [Patient Registry]|
|Study Design:||Observational Model: Case Control
Time Perspective: Prospective
|Target Follow-Up Duration:||2 Years|
|Official Title:||Cancer in Elderly Nursing Home Residents in Belgium: Prospective Cohort Study Including Translational Research to Develop Better Prognostic Tools to Help With Treatment Decisions in the Elderly|
- Prognostic capacity of p16INK4a expression in T lymphocytes on Overall Survival [ Time Frame: The analyses will be performed when 90 deaths will have been observed ] [ Designated as safety issue: No ]
- Demographics, referral patterns and motives for non-referral, anti-cancer treatments and outcome in nursing home patients with cancer or with strong clinical suspicion of cancer. [ Time Frame: Baseline, every 3 months and for max. 2 years ] [ Designated as safety issue: No ]
- Comparison of baseline parameters and outcome between nursing home cancer patients (cancer patient cohort) and nursing home non-cancer patients (control cohort) [ Time Frame: Baseline, every 3 months and for max. 2 years ] [ Designated as safety issue: No ]
- Prognostic capacity of baseline clinical markers and Porock scale on OS, functional decline, cognitive decline and Quality of Life separately in nursing home cancer group (cancer patient cohort) and non-cancer group (control cohort). [ Time Frame: Baseline, every 3 months and for max. 2 years ] [ Designated as safety issue: No ]
- Prognostic capacity of other biomarkers of ageing on OS in the control group of nursing home patients without cancer. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
|Estimated Primary Completion Date:||December 2015 (Final data collection date for primary outcome measure)|
Nursing home residents without cancer
Cancer patient cohort
Patients in nursing homes with suspected or diagnosed active invasive cancer where a diagnostic or treatment decision has to be taken
Subgroup of individuals in the control cohort willing to provide a blood sample
|Contact: Nicolas Dif, PhD||+32 2 774 10 firstname.lastname@example.org|
|Armonea nursing homes network||Not yet recruiting|
|Study Chair:||Hans Wildiers||UZ Leuven, Belgium|